Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer （ALTER-L029）

Condition:   Non-Small Cell Lung Cancer Stage III Intervention:   Drug: Anlotinib Sponsor:   Anhui Shi, MD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials